Diffusion Study on Patients With Osteosarcoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01615640|
Recruitment Status : Unknown
Verified June 2012 by Dr. Thekla von Kalle, Klinikum Stuttgart.
Recruitment status was: Recruiting
First Posted : June 8, 2012
Last Update Posted : June 8, 2012
|Condition or disease|
Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging have the potential to measure early cellular and vascular changes that occur in response to chemotherapy and could therefore be early predictors of therapeutic response.
Aim of our study is to assess the accuracy of dynamic contrast enhanced and diffusion-weighted MR imaging in evaluating response to chemotherapy during the preoperative treatment of osteosarcoma. Patients will undergo dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging before, during and after chemotherapy.
Our long-term goal is to use these imaging techniques to develop non-invasive methodologies that would be better predictors of tumor response than the current clinical standard and earlier predictors than histological evaluation of the whole tumor.
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Monitoring the Response of Osteosarcoma Under Neoadjuvant Chemotherapy: The Value of Dynamic Contrast Enhancement and Diffusion-weighted MRI|
|Study Start Date :||September 2010|
Patients with an histologically proven osteosarcoma will be entered into the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01615640
|Contact: Thekla von Kalle, Doctor||+49 (0) 711/ email@example.com|
|Stuttgart, Baden-Württemberg, Germany, 70176|
|Principal Investigator:||Thekla von Kalle, Doctor||Klinikum Stuttgart|